White Oak Resiliency Act of 2025

Senate Bill

S. 476

119th Congress

White Oak Resiliency Act of 2025

In Committee

Introduced:Jun 3, 2025

Primary Sponsor

Robert Menendez

D - NJ

Cosponsors

3

Quick Stats

Policy Area

Health

Summary

This bill would require certain prescription drugs to have been on the market for at least 11 years before they can be considered for the Medicare Drug Price Negotiation Program. This program allows the government to negotiate the prices of certain drugs covered by Medicare.

Latest Action

Read twice and referred to the Committee on Finance.

Introduced6/3/2025

StatusRead twice and referred to the Committee on Agriculture, Nutrition, and Forestry.

ChamberSenate

Data from Congress.gov

See this page through your district lens

Enter ZIP to personalize representatives and vote context.

Stay on top of this issue

Subscribe for weekly bill and representative updates.

Vote Prediction

White Oak Resiliency Act of 2025

This bill would require certain prescription drugs to have been on the market for at least 11 years before they can be considered for the Medicare Drug Price Negotiation Program. This program allows the government to negotiate the prices of certain drugs cover

Community Breakdown

Pass

0%

Fail

0%

0 predictions

This bill would require certain prescription drugs to have been on the market for at least 11 years before they can be considered for the Medicare Drug Price Negotiation Program. This program allows the government to negotiate the prices of certain drugs covered by Medicare.

Bill Number: 476
Introduced: 6/3/2025
Status: Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
Policy Area: Health

Data from Congress.gov

AI-generated summary

Fact Sheet

Title: White Oak Resiliency Act of 2025
Bill Number: 476
Sponsor: No sponsor
Status: Read twice and referred to the Committee on Agriculture, Nutrition, and Forestry.
Introduced: 6/3/2025
Summary: This bill would require certain prescription drugs to have been on the market for at least 11 years before they can be considered for the Medicare Drug Price Negotiation Program. This program allows the government to negotiate the prices of certain drugs covered by Medicare.

Data from Congress.gov

AI Summary

Plain-English explanation of this bill

This bill would require certain prescription drugs to have been on the market for at least 11 years before they can be considered for the Medicare Drug Price Negotiation Program. This program allows the government to negotiate the prices of certain drugs covered by Medicare.

Last updated: 12/30/2025

Official Summary

Congressional Research Service summary

Maintaining Investments in New Innovation Act This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Key Points

Main provisions of the bill

The bill extends the market approval requirement from 7 years to 11 years for drugs to qualify for the Medicare Drug Price Negotiation Program.
The Medicare Drug Price Negotiation Program allows the government to negotiate prices for certain prescription drugs covered by Medicare.
This change would delay when some new drugs could be considered for the price negotiation program.

How This Impacts Americans

Potential effects on citizens and communities

If this bill becomes law, it would impact Medicare beneficiaries by potentially delaying when some new prescription drugs could have their prices negotiated under the Medicare program. This could affect the costs that seniors and people with disabilities pay for those medications.

Policy Areas

Primary Policy Area

Health

Related Subjects

Genetics

Medicare

Prescription drugs

Scope & Jurisdiction

Jurisdiction Level

federal

Congressional Session

119th Congress

Citation Reference

476, 119th Congress (2025). "White Oak Resiliency Act of 2025". Source: Voter's Right Platform. https://votersright.org/bills/118-s-476

Public Opinions

Community submissions related to this bill.

Share your opinion

No public opinions yet. Be the first to submit one for this bill.

Related Bills in Health

HR 3021

Empowering Patient Choice of Medical Care Act

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

HR 2111

To amend the Federal Food, Drug, and Cosmetic Act to exempt the premium cigar industry from certain regulations.

Referred to the House Committee on Energy and Commerce.

HR 2884

Anti-Racism in Public Health Act of 2025

Referred to the House Committee on Energy and Commerce.

S 1406

SOAR Act of 2025

Read twice and referred to the Committee on Finance.